Let me put it another way. It is untenable that a company has regulatory approval to diagnose a raft of respiratory disease that can be delivered cheaply, globally and virtually instantaneously, has a market cap of < AUD$70m. And so few partners and traction. What we have is bigger than what our senior management can cope with. Remarkable achievement in getting us to this position, but now we need help.
RAP Price at posting:
8.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
